文献速递青光眼白内障与屈光手术

Schlemm管微支架联合白内障手术降低开角型青光眼眼压:HORIZON研究

A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study.
PubMed 文献 · Ophthalmology · 2018-06-23

HORIZON研究为前瞻性多中心单盲随机对照试验,纳入369眼POAG合并白内障患者,按2:1随机接受Schlemm管微支架(HMS)联合超声乳化或单纯超声乳化(NMS)。24个月时HMS组无药MDIOP降幅≥20%的比例为77.3%,NMS组为57.8%(差异19.5%,95%CI 11.2%-27.8%,P<0.001);HMS组平均MDIOP降幅-7.6±4.1 mmHg,NMS组-5.3±3.9 mmHg(差异-2.3 mmHg,95%CI -3.0至-1.6,P<0.001)。HMS组用药数从基线1.7±0.9降至24个月0.3±0.8,NMS组从1.7±0.9降至0.7±0.9(差异-0.4种,P<0.001);无与微支架相关的严重眼部不良事件,两组安全性参数无显著差异。

要点

  • HMS联合超声乳化较单纯超声乳化显著提高24个月无药MDIOP降幅≥20%的比例(77.3% vs 57.8%,P<0.001)。
  • HMS组24个月无药MDIOP平均降幅-7.6±4.1 mmHg,NMS组-5.3±3.9 mmHg,组间差异-2.3 mmHg(95%CI -3.0至-1.6,P<0.001)。
  • HMS组24个月平均用药数0.3±0.8,NMS组0.7±0.9,组间差异-0.4种(P<0.001);无微支架相关严重眼部不良事件。

核心结论

  • 在轻中度POAG合并白内障患者中,Schlemm管微支架联合超声乳化较单纯超声乳化在24个月时无药MDIOP降幅和用药减少方面更优。

研究设计与样本

  • 前瞻性、多中心、单盲、随机对照试验,纳入POAG合并白内障且洗脱后MDIOP 22-34 mmHg的患眼,按2:1随机接受HMS联合超声乳化(369眼)或单纯超声乳化(187眼)。

主要发现

  • 24个月时无药MDIOP降幅≥20%的比例HMS组77.3% vs NMS组57.8%,差异19.5%(95%CI 11.2%-27.8%,P<0.001)。
  • 24个月无药MDIOP平均降幅HMS组-7.6±4.1 mmHg vs NMS组-5.3±3.9 mmHg,差异-2.3 mmHg(95%CI -3.0至-1.6,P<0.001)。
  • 平均用药数HMS组从基线1.7±0.9降至24个月0.3±0.8,NMS组从1.7±0.9降至0.7±0.9,差异-0.4种(P<0.001)。
  • 无与微支架相关的严重眼部不良事件,两组安全性参数无显著差异。

关键数值与推荐

  • 主要终点:24个月无药MDIOP降幅≥20%的受试者比例;次要终点:24个月无药MDIOP较基线的平均变化。
  • 纳入标准:POAG合并白内障,洗脱后MDIOP 22-34 mmHg。

临床怎么用

  • 对于POAG合并白内障且洗脱后MDIOP 22-34 mmHg的患者,超声乳化联合Schlemm管微支架较单纯超声乳化可更大幅降低无药MDIOP并减少降压药物使用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare cataract surgery with implantation of a Schlemm canal microstent with cataract surgery alone for the reduction of intraocular pressure (IOP) and medication use after 24 months. DESIGN: Prospective, multicenter, single-masked, randomized controlled trial. PARTICIPANTS: Subjects with concomitant primary open-angle glaucoma (POAG), visually significant cataract, and washed-out modified diurnal IOP (MDIOP) between 22 and 34 mmHg. METHODS: Subjects were randomized 2:1 to receive a single Hydrus Microstent (Ivantis, Inc, Irvine, CA) in the Schlemm canal or no stent after uncomplicated phacoemulsification. Comprehensive eye examinations were conducted 1 day, 1 week, and 1, 3, 6, 12, 18, and 24 months postoperatively. Medication washout and MDIOP measurement were repeated at 12 and 24 months. MAIN OUTCOME MEASURES: The primary and secondary effectiveness end points were the proportion of subjects demonstrating a 20% or greater reduction in unmedicated MDIOP and change in mean MDIOP from baseline at 24 months, respectively. Hypotensive medication use was tracked throughout the course of follow-up. Safety measures included the frequency of surgical complications and adverse events. RESULTS: A total of 369 eyes were randomized after phacoemulsification to Hydrus Microstent (HMS) and 187 to no microstent (NMS). At 24 months, unmedicated MDIOP was reduced by ≥20% in 77.3% of HMS group eyes and in 57.8% of NMS group eyes (difference = 19.5%, 95% confidence interval [CI] 11.2%-27.8%, P < 0.001). The mean reduction in 24-month unmedicated MDIOP was -7.6±4.1 mmHg (mean ± standard deviation) in the HMS group and -5.3±3.9 mmHg in the NMS group (difference = -2.3 mmHg; 95% CI, -3.0 to -1.6; P < 0.001). The mean number of medications was reduced from 1.7±0.9 at baseline to 0.3±0.8 at 24 months in the HMS group and from 1.7±0.9 to 0.7±0.9 in the NMS group (difference = -0.4 medications; P < 0.001). There were no serious ocular adverse events related to the microstent, and no significant differences in safety parameters between the 2 groups. CONCLUSIONS: This 24-month multicenter randomized controlled trial demonstrated superior reduction in MDIOP and medication use among subjects with mild-to-moderate POAG who received a Schlemm canal microstent combined with phacoemulsification compared with phacoemulsification alone.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. Ophthalmology. 2018. PMID: 29945799. doi:10.1016/j.ophtha.2018.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。